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ABSTRACT  1	
Background: There are conflicting views in the literature as to whether vitamin D2 and 2	
vitamin D3 are equally effective at raising and maintaining serum concentrations of 25-3	
hydroxyvitamin [25(OH)D], particularly at lower doses of vitamin D.   4	
Objective: We aimed to investigate whether vitamin D2 or vitamin D3 fortified in juice or 5	
food, at a relatively low dose of 15 µg/d, was effective in raising serum total 25(OH)D and to 6	
compare their respective efficacy  in South Asian and white European women over the winter 7	
months, within the setting of a large randomized-controlled trial. 8	
Design: A randomized, double-blind, placebo-controlled, food fortification trial was 9	
conducted in healthy South Asian and white European women aged 20-64 y (n = 335; Surrey, 10	
UK) who consumed either placebo, 15 µg vitamin D2 juice, 15 µg vitamin D2 biscuit, 15 µg 11	
vitamin D3 juice or 15 µg vitamin D3 biscuit daily for 12 wk. Serum 25(OH)D was measured 12	
by liquid-chromatography tandem mass spectrometry (LC/MS-MS) at baseline, week 6 and 13	
week 12 of the study.  14	
Results: Post-intervention, in the two ethnic groups combined, both the D3 biscuit and the D3 15	
juice groups demonstrated a significantly greater absolute incremental change (Δ) in total 16	
25(OH)D when compared to the D2 biscuit group (Δ 15.3nmol/l [95% CI 7.4, 23.3], p<0.0003 17	
and Δ16.0nmol/l [95% CI 8.0, 23.9], p<0.0001), the D2 juice group (Δ 16.3nmol/l [95% CI 18	
8.4, 24.2], p<0.0001 and Δ 16.9nmol/l [95% CI 9.0, 24.8], p<0.0001), and the placebo group 19	
(Δ 42.3nmol/l [95% CI 34.4, 50.2], p<0.0001 and Δ 42.9nmol/l [95% CI 35.0, 50.8], 20	
p<0.0002).  21	
Conclusions: Using a daily dose of vitamin D relevant to public health recommendations (15 22	
µg) and in vehicles relevant to food fortification strategies, vitamin D3 was more effective 23	
than vitamin D2 in raising serum 25(OH)D in the wintertime. Vitamin D3 may therefore be a 24	
preferential form to optimize vitamin D status within the general population.  25	
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INTRODUCTION  28	
Historically, it has been suggested that there is no difference between vitamin D2 29	
(ergocalciferol) and vitamin D3 (cholecalciferol) in their effectiveness in improving vitamin D 30	
status (1-4). We and others have challenged this thinking (5), controversially (6). Over the 31	
past two decades, a number of trials have been completed comparing the relative efficacy of 32	
vitamin D2 versus D3 in raising serum total 25-hydroxyvitamin D (25(OH)D; the biological 33	
marker widely used to indicate vitamin D status), with mixed results. Whilst there is strong 34	
evidence that in large bolus doses vitamin D3 is the more efficacious form (7-10), for lower 35	
doses the evidence is contradictory (11-13). From a meta-analysis published in 2012, it is 36	
clear that the studies have small cohort sizes and are consequently under-powered, and there 37	
is a large variation in the dosage and frequency of administration of vitamin D between 38	
studies (14). Hence, to date, no studies have been able to comprehensively answer two 39	
questions: 1) whether there is a significant difference in efficacy between vitamin D2 and D3 40	
in raising total 25(OH)D, and if so, 2) whether the recommended daily allowance (RDA) of 41	
vitamin D in either form achieves and maintains a 25(OH)D concentration within an 42	
acceptable range for health?  43	
Aside from the scientific interest in vitamin D, understanding and quantifying the 44	
comparative efficacy of vitamin D2 and D3 on total 25(OH)D is important to ensure that 45	
public health advice is as effective as possible in preventing vitamin D deficiency across the 46	
population. Current guidance given by the US National Institute of Health (NIH), the UK 47	
Department of Health, and other government bodies around the world, is that the two forms of 48	
vitamin D are equivalent and can be used to equal effect; although the NIH do acknowledge 49	
that vitamin D3 offers greater efficacy when given in bolus doses. 50	
In populations living at northerly latitudes, where there is an absence of UVB rays for 51	
endogenous vitamin D synthesis between the months of October to March alongside the 52	
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limited dietary sources of vitamin D, it is firmly established that vitamin D status is 53	
inadequate during the winter months (15-16). The diversity of ethnic backgrounds within such 54	
populations adds further complexity to the issue; Darling and colleagues have shown that in 55	
the UK those of South Asian origin were deficient (25(OH)D <30nmol/l) the entire year-56	
round, irrespective of available dietary or UV sources of vitamin D (16).   57	
Extending the use of vitamin D food fortification may be a key strategy in alleviating the risk 58	
of vitamin D deficiency within the population. However, given the current controversy 59	
surrounding the efficacy of vitamin D2 and D3, it is not yet clear whether either form may be 60	
the preferred option for food fortification in order to maximise the potential beneficial impact 61	
at a population-wide level.  62	
The primary aim of the D2-D3 Study was to use a food-fortification model, designed to 63	
compare the efficacy of 15 µg/d (Institute of Medicine [IOM] RDA) of vitamin D2 versus 64	
vitamin D3 in raising serum total 25(OH)D in South Asian and white European women during 65	
the wintertime in the United Kingdom.     66	
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METHODS 67	
Subjects 68	
A total of 335 healthy, free living South Asian or white European women aged 20-64 y were 69	
recruited in this 12-wk food fortification intervention trial. Subjects were recruited in the 70	
Surrey (UK) area through the use of local contacts and advertisements, as well as through 71	
local GP surgeries with permission and support from the National Institute for Health 72	
Research Clinical Research Network (UKCRN ID 10695). The inclusion criteria ensured all 73	
participants were in good health, white European or South Asian (i.e. originating from India, 74	
Bangladesh, Pakistan or the Arabian Peninsula). Participants were also either pre-menopause, 75	
or >3 y post-menopause. Volunteers were excluded if they were unwilling to discontinue the 76	
consumption of vitamin D-containing supplements 4 wk before the initiation of the study and 77	
throughout the study. Volunteers were also excluded if they were regular sun-bed users or if 78	
they had been on a sunshine vacation within 4 wk before the initiation of the study, or planned 79	
to take a sunshine vacation during the 12 wk intervention. The exclusion criteria also included 80	
pregnancy and breastfeeding, malabsorption syndromes (i.e. coeliac disease), renal failure and 81	
any health conditions or use of medications that interfered with vitamin D metabolism or bone 82	
turnover.  83	
 84	
Study design and randomization 85	
This was a 12-wk double-blind, randomized, placebo-controlled, parallel food fortification 86	
trial based at the University of Surrey (UK). As described in Figure 1 (Consolidated 87	
Standards of Reporting Trials (CONSORT) flow diagram (17)), participants were allocated to 88	
one of five treatment groups: placebo juice with placebo biscuit (placebo); 15 µg vitamin D2 89	
juice with placebo biscuit (D2J); placebo juice with 15 µg vitamin D2 biscuit (D2B); 15 µg 90	
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vitamin D3 juice with placebo biscuit (D3J) and placebo juice with 15 µg vitamin D3 biscuit 91	
(D3B).  92	
 93	
Participants were allocated to a treatment group via a randomized allocation system using a 94	
computer-generated randomization programme generated by the trial statistician. The 95	
randomization was stratified to take into account the participants’ ethnicity, BMI and age, and 96	
was verified by the trial statistician with the codes assigned to the participants by a trial 97	
investigator (the investigator was blinded to the randomization). The trial statistician was 98	
responsible for keeping the code. The codes were shared with Campden BRI (Chipping 99	
Campden, UK) and the experimental intervention products were assigned the respective code 100	
during the packaging process by the manufacturers.  101	
 102	
This D2-D3 Study took place over two consecutive winters (October 2011 to March 2012 and 103	
October 2012 to March 2013), to avoid interference of UV exposure on vitamin D status. The 104	
participants attended three face-to-face individual study appointments at the Clinical 105	
Investigation Unit (University of Surrey); one at the start of the trial (week 0), the middle 106	
(week 6) and the end (week 12). Participants were given intervention products (juice and 107	
biscuits) based on their randomization code at the start of the trial, and were requested to 108	
consume one juice and one biscuit per day for 12 wk. At all visits, a standardised set of 109	
anthropometrics were recorded (Table 1), in addition to a fasting blood sample to measure 110	
serum total 25(OH)D, 25(OH)D2, 25(OH)D3, calcium, albumin and parathyroid hormone 111	
(PTH) (Table 2). All blood samples were stored at -80°C prior to analysis. At the baseline and 112	
final visit participants were requested to complete a 4-day diet diary to assess dietary intakes, 113	
and wear a dosimeter (polysulphone badge) for seven days on their outer clothing to measure 114	
exposure to UV radiation.  115	
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Intervention Products 116	
The intervention products were formulated and manufactured by Campden BRI (Chipping 117	
Campden, UK) (Juice (210g serving) 305.6 kJ, 0.2g fat, 0.9g protein, 17.6g carbohydrate, 118	
17.2mg calcium; Biscuit (17g serving) 321.0 kJ, 3.6g fat, 1.0g protein, 10.6g carbohydrate, 119	
15.6mg calcium) as either a placebo or were fortified with 15 µg of vitamin D2 or vitamin D3. 120	
Hemi-cellulose micro-encapsulated vitamin D2 and D3 (Lycored, Kent, UK) was added to the 121	
respective juice and biscuits during manufacture. High performance liquid chromatography 122	
tandem mass spectrophotometry (LC MS/MS) was used to determine the amount and stability 123	
of vitamin D2 and D3 in the orange juice and biscuits. The products were found to contain 124	
either no vitamin D2 or D3 (placebo) or vitamin D within 10% of their specified 125	
concentrations. Concentration of vitamin D2 and D3 was found to be stable after storage at 126	
room temperature for three months. 127	
 128	
Laboratory Analysis 129	
Serum 25(OH)D 130	
Serum 25(OH)D, 25(OH)D2 and 25(OH)D3 concentrations were determined by LC-MS/MS 131	
using an AB Sciex 5500 tandem mass spectrophotometer (AB Sciex UK Ltd, Warrington, 132	
UK) and the MassChrom ® 25(OH)D3/D2 kit for LC-MS/MS (Chromsystems Instruments and 133	
Chemicals GmbH, Gräfelfing, Germany) following the manufacturers’ instructions. 134	
Laboratory intra- and inter-assay CVs were 3.7% and 4.8% respectively. The Manchester  135	
laboratory is accredited by CPA UK (CPA number 0865) and has been certified as proficient 136	
by the Vitamin D Quality Assurance Scheme (DEQAS).  137	
 138	
 139	
 140	
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Serum calcium, albumin and parathyroid hormone 141	
Calcium, albumin and PTH concentrations were measured by Surrey Pathology Services 142	
(Frimley, Camberley, UK). Serum calcium was measured using an endpoint 143	
spectrophotometric reaction based on the o-cresolphthalein complexone (CPC) methodology, 144	
and serum albumin was measured using an endpoint spectrophotometric reaction based on the 145	
bromocresol green solution (BCG) dye binding methodology, both using the ADVIA 2400 146	
Chemistry System (Siemens Healthcare Diagnostics Ltd, Frimley, Camberley, UK). 147	
Manufacturer’s quoted inter- and intra-assay CVs for calcium were 1.9% and 1.1% 148	
respectively, and for albumin were 1.3% and 0.6% respectively. Serum calcium 149	
concentrations were adjusted for albumin concentrations. Plasma intact PTH was measured 150	
using a two-site sandwich chemiluminescent immunoassay using the ADVIA Centaur XP 151	
Immunoassay System (Siemens Healthcare Diagnostics Ltd, Frimley, Camberley, UK). 152	
Manufacturer’s quoted inter- and intra-assay CVs were 3.4% and 4.0% respectively.  153	
 154	
Assessment of dietary intakes, UV exposure and compliance 155	
Dietary intakes were determined by inputting diet diary data (following a generic foods 156	
protocol) into the dietary analysis programme DietPlan6 (Forestfield Software Ltd, Horsham, 157	
UK), with standardised portion sizes obtained from the ‘Food Portion Sizes’ book (The 158	
Stationary Office, UK). UV exposure was measured by reading both pre- and post-159	
intervention dosimeters at 330nm using a Cecil Aquarius CE7200 Double Beam 160	
Spectrophotometer (Cecil Instruments Ltd, Cambridge UK) to detect the change in 161	
absorbency. Results were then converted to Standard Erythemal Dose (SED) as previously 162	
described (16). Participant compliance to the study was assessed through a one-to-one 163	
interview with a researcher, and a packet count, at both week 6 and week 12. Regular 164	
 12 
	
 
	
telephone contact (minimum fortnightly) assisted in encouraging and monitoring participant 165	
compliance through the duration of the study.  166	
 167	
Ethical approval 168	
This study received ethical approval from the South-East Coast (Surrey) National Health 169	
Service Research Ethics Committee (11/LO/0708) and the University of Surrey Ethics 170	
Committee (EC/2011/97/FHMS). All participants gave written informed consent in agreement 171	
with the Helsinki Declaration prior to commencing study activities; the full study protocol is 172	
available as a supplementary file.  173	
 174	
Statistical analyses  175	
The response of serum total 25(OH)D concentrations to vitamin D2 or D3 was the primary 176	
end-point, and formed the basis of the sample size calculations. A total of 320 subjects (white 177	
European n 240, South Asian n 80) at 90% power were required to: (i) detect a 0.6 SD effect 178	
size in serum 25(OH)D levels between placebo and 15µg in white European women for 179	
vitamin D2 vs. vitamin D3; (ii) detect a 1.1 SD effect size in serum 25(OH)D levels between 180	
placebo and 15µg  in South Asian women for vitamin D2 vs. vitamin D3.  181	
 182	
The biochemical data were analysed using SAS 9.2 (SAS Institute Inc, NC, USA), on the 183	
basis of intention-to-treat, and were analysed a) as non-transformed data to bring out 184	
increments relative to baseline (absolute and delta values) and b) as logarithmically-185	
transformed data to bring out increments as percentage relative to baseline values. The data 186	
were then submitted to a general linear mixed model, using SAS PROC MIXED.   Model 187	
independent variables were: baseline 25OHD status, age, BMI, ethnicity (white European and 188	
South Asian), time visit (the visits were: visit 1, for the model baseline covariate; visits 2 and 189	
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3, the two post-intervention visits).  In the modelling, visit was a two-level (visits 2 and 3) 190	
repeated measure with unstructured variance-covariance matrix), intervention group (control 191	
group, D2 group and D3 group) and the following interactions – a) time visit by intervention 192	
group interaction; b) time visit by ethnicity interaction; c) ethnicity by intervention group 193	
interaction and d) time visit by ethnicity by intervention group interaction. Subject was a 194	
model random effect. The ‘time visit’ and ‘subject’ variables were modelled as random 195	
effects, the remaining independent variables were modelled as fixed effects.     196	
In addition to including the above-mentioned four interaction terms as independent variables 197	
in our general linear mixed model, we tested the statistical significance of each of these 198	
interactions.    199	
 200	
Missing data was treated in the modelling as being missing at random, with only the non-201	
missing data being submitted to the general linear mixed model.   The 95% confidence intervals 202	
and p values, involving contrasts adjusted for baseline, were used to obtain the statistical results 203	
quoted below, and were obtained using the ESTIMATE statement of SAS PROC MIXED, as 204	
well as the PDIFF option of the LSMEANS statement of SAS PROC MIXED. Contrast 205	
estimates for logarithmically-transformed data were expressed as percentage differences.  We 206	
applied multiplicity correction to both the primary and secondary objectives using Bonferroni 207	
adjustment for a total of 18 p values; significance was therefore only accepted at p<0.003 208	
[p<0.05/18]).   We give details of the Bonferroni-adjusted significance throughout the results 209	
section.   We did not apply the Bonferroni correction to the interaction testing.  The data for 210	
25(OH)D2 (and corrected calcium in certain instances) did not allow modelling of the non-211	
logarithmically transformed data to be performed and thus this variable is only described as 212	
percentage (%) change relative to baseline, not absolute. For ease of comparison, 25(OH)D2, 213	
25(OH)D3, parathyroid hormone and corrected calcium are presented as relative (%) change 214	
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relative to baseline (not absolute increments) within the text of the manuscript, with the 215	
geometric mean values presented in Table 3 also generated from the logarithmically 216	
transformed data. 217	
 218	
  219	
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RESULTS 220	
Baseline participant characteristics  221	
A total of 335 women were randomised and entered into the D2-D3 Study, forming five 222	
intervention groups.  These are shown in Table 1. The study was carried out over two 223	
consecutive winter periods (Oct 2011-Mar 2012 and Oct 2012-Mar 2013) and participants 224	
were recruited between Oct-Jan 2012 and July-Jan 2013 respectively.   As described in 225	
Figure 1, a total of 525 individuals were initially assessed for inclusion, with 190 deemed 226	
ineligible and 335 proceeding to join the study.  Participant numbers (both ethnic groups 227	
combined) per intervention group were between n 65 to n 70. The numbers for the white 228	
European group in each randomisation category were between n 48 to n 51.    The numbers 229	
for the South Asian group in each randomisation category were n 17 to n 19.    The drop-out 230	
rate equated to 13.1% (n 44). However, all participants who commenced the study were 231	
included in the final analysis (Intention-To-Treat). We did not check for significant 232	
differences at baseline since the groups were randomly assigned and so any differences at 233	
baseline would have been explained by chance (Tables 1-3). 234	
 235	
Significance testing for interactions 236	
Results for the significance levels of the tests of interaction were as follows:  The a) time visit 237	
x intervention group interaction term was significant for all the primary and secondary 238	
objective outcome measurements including total 25(OH)D status, PTH, 25(OH)D2 and 239	
25(OH)D3 (p<0.0004 to p<0.0001 respectively).   For total 25(OH)D status, there was a non-240	
significant trend for  b) time visit x ethnicity (p<0.066) but no significant differences for  c) 241	
intervention group x ethnicity or d) time visit x intervention group x ethnicity.  For PTH, b) 242	
time visit x ethnicity interaction was not significant and neither was c) intervention group x 243	
ethnicity.   For d) time visit x intervention group x ethnicity interaction, this was significant 244	
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(p<0.04).   For 25(OH)D2, b) no significant interactions were found for time visit x ethnicity, 245	
but for c) a significant interaction was shown for intervention group x ethnicity (p<0.001),  246	
and for d) time visit x intervention group x ethnicity (p<0.01).  Similar findings were found 247	
for 25(OH)D3:  b) time visit x ethnicity interaction was significant (p<0.0067) and  c) 248	
intervention group x ethnicity interaction was significant (p<0.0001) and d)  a non-significant 249	
trend for time visit x intervention group x ethnicity interaction (p<0.1).    250	
 251	
Total  serum 25(OH)D concentrations in the two ethnic groups combined 252	
As described in Table 2, the placebo group experienced a 25% reduction in total 25(OH)D 253	
over the 12-week intervention (Week 0: 44.8 nmol/l [95% CI 37.5, 52.1], Week 12: 33.5 254	
nmol/l [95% CI 27.8, 39.3], Δ -11.2 nmol/l [95% CI -16.7, -5.8], (p<0.0001)).   255	
 256	
When the data for the two ethnic groups were combined, both vitamin D2 fortification 257	
products demonstrated a substantial impact upon total 25(OH)D concentrations, with a 33% 258	
and 34% increase over the course of the intervention for the D2J and D2B groups 259	
respectively. The vitamin D3 fortification products demonstrated even greater effects, with the 260	
D3J and D3B groups increases in total 25(OH)D in the order of 75% and 74% respectively.  261	
 262	
When comparing across intervention groups and considering change from baseline, the D3J 263	
group also demonstrated a significantly higher absolute change in total 25(OH)D 264	
concentrations over the course of the intervention when compared to D2J (Δ 16.9nmol/l [95% 265	
CI 9.0, 24.8], (p<0.0005), D2B (Δ16.0nmol/l [95% CI 8.0, 23.9], (p<0.0003) and placebo (Δ 266	
42.9nmol/l [95% CI 35.0, 50.8], (p<0.0005).  In addition, the D3B group demonstrated a 267	
significantly higher absolute change in total 25(OH)D when compared to the D2B group (Δ 268	
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15.3nmol/l [95% CI 7.4, 23.3], p<0.0003), the D2J group (Δ 16.3nmol/l [95% CI 8.4, 24.2],  269	
(p<0.0005), and the placebo group (Δ 42.3nmol/l [95% CI 34.4, 50.2], (p<0.0003).  270	
 271	
No significant difference in absolute change between the D3J and D3B groups was detected 272	
over the time course of the intervention, thus indicating equivalent bioavailability (Δ 273	
0.6nmol/l [95% CI -7.4, 8.6] (p<0.34). Similarly, for the D2J and D2B groups, no significant 274	
difference in absolute change for total 25(OH)D concentrations was detected between the two 275	
groups over the course of the intervention (Δ 0.9nmol/l [95% CI -6.9, 8.7], (p <0.25). 276	
 277	
Since there were no significant interactions for ethnicity, we did not analyse further the 278	
25OHD status for the Caucasian and South Asian groups separately.   However we observed 279	
from the data (Table 2) that the South Asian women appeared to have a greater response to 280	
the vitamin D (both D2 and D3) compared to Caucasian women, likely due to their lower 281	
25(OH)D status at baseline (<30nmol/l in all South Asian groups).  We also observed that in 282	
those South Asian women in the vitamin D2 group, 25OHD status did not reach 50nmol/l at 283	
the end of the 12 week period but those taking the vitamin D3 juice did.   When considering 284	
only those South Asian participants who completed the entire intervention (n 63, 71% 285	
completion), 72.7% of those South Asian women who consumed either vitamin D3 product 286	
attained levels >50nmol/l whereas only 55.6% of SA participants consuming either D2 287	
product met the same serum 25(OH)D threshold.   For the white European women who 288	
completed the study (n 228, 93% completion), all of those participants in the D3B and D3J 289	
groups achieved serum 25(OH)D levels >50nmol/l at the end of the intervention. In contrast, 290	
90.9% of participants from the D2B and 89.4% from the D2J groups met the threshold 291	
of >50nmol/l post-intervention. When combining the D2 groups, the attainment rate was 292	
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90.1%. For the placebo group, all SA women were below the 50nmol/l cut-off at the end of 293	
intervention, yet 42% of EU women were maintaining total 25(OH)D levels >50nmol/l.  294	
 295	
Serum parathyroid hormone concentrations in two ethnic groups combined 296	
Importantly, the parathyroid hormone (PTH) responded to the vitamin D in the direction 297	
expected physiologically (Table 3). Considering the percentage change from baseline, there 298	
were Bonferroni-corrected non-significant trends for reductions for the D2J, D3J and D3B 299	
groups (p<0.03), however there were no significant changes for the placebo and D2B groups. 300	
For corrected calcium (all groups), the post-intervention concentrations were significantly 301	
higher when compared relatively to the baseline (p<0.0001), however serum levels remained 302	
within the normal range expected clinically (Table 3).  303	
 304	
Serum 25(OH)D2 and 25(OH)D3 concentrations in two ethnic groups combined 305	
Given the fact that no significant differences were detected between the juice and biscuit 306	
groups within their respective vitamin D2 and D3 fortification strands, the groups’ juice and 307	
biscuit data were aggregated to explore the response of 25(OH)D2 and 25(OH)D3 over the 308	
course of the intervention (taking into account the baseline values). As described in Figure 309	
2A, for the aggregated vitamin D2 intervention group (n 133), over the course of the 310	
intervention, there was a significant increase in 25(OH)D2 compared to both the placebo 311	
(Estimated Percentage Difference [EPD] 2328.8% [95% CI 1717.4, 3113.7] (p<0.0002)) and 312	
D3 groups (EPD 3018.7% [95% CI 2353.3, 3864.6] (p<0.0002)).  For the 25(OH)D3 response 313	
(Figure 2B), the aggregated D3 intervention group (n 137) exhibited a significantly greater 314	
response over the course of the intervention when compared to the placebo (EPD 185.8% 315	
[95% CI 148.4, 228.7] (p<0.0001)) and D2 groups (EPD 281.9% [95% CI 242.1, 326.3] 316	
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(p<0.0001)), however there was also a significant difference in 25(OH)D3 responses between 317	
the D2 and placebo groups (EPD 33.6% [95% CI 16.2, 52.2] (p<0.0001)). 318	
 319	
Fortification product compliance 320	
There was a dropout rate of 13.1% (n 44) over the course of the study (Figure 1), with a 71% 321	
completion rate for the south Asian women and 93% completion rate for the white European 322	
women (mean completion rate across the intervention groups per ethnicity). Reasons for drop-323	
out included dislike of food products/unwilling to comply (n 3), unable to tolerate products 324	
with reports of nausea or heartburn (n 5), unable to obtain blood sample at mid-intervention or 325	
final visit (n 6), change in family circumstances (n 7), moved from area (n 3), unwell during 326	
trial and feeling unable to continue (n 3), and a number were lost to follow-up (n 17). The 327	
participants who did complete the study demonstrated excellent compliance. On average, 328	
participants consumed 94% of the products allocated to them, which translated into the 329	
participants missing on average four biscuit and five juice portions over the course of the 330	
intervention. The South Asian participants reported missing on average eight biscuit portions 331	
and 11 juice portions, the white European participants missed an average of three biscuits and 332	
four juice administrations. 333	
 334	
Dietary Intakes and UVB Exposure 335	
Dietary analysis confirmed the average intake of dietary vitamin D for the entire cohort at 336	
baseline to be 2.7 ± 2.3µg per day (78.2% response rate, n 262). Mean intake for key nutrients 337	
was as follows: Energy 7969.5 ± 1864.6kJ, Total Fat 78.6 ± 26.2g, Protein 72.8 ± 18.1g, 338	
Carbohydrate 204.7 ± 51.7g and Calcium 849.1 ± 260.9mg. 339	
Participants’ UV exposure for the duration of the trial was minimal, with a mean exposure of 340	
0.035 ± 0.039SED pre-intervention and 0.086 ± 0.137SED post-intervention for the cohort.   341	
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DISCUSSION  342	
This study investigated whether vitamin D2 or vitamin D3 fortified in juice or food, at a 343	
relatively low dose of 15 µg/d, was effective in raising serum total 25(OH)D and compared 344	
the respective efficacy of these two forms of vitamin D in South Asian and white European 345	
women over the winter months.  Whilst both vitamin D2 and vitamin D3 increased 25(OH)D 346	
status and prevented the decline in 25(OH) D status during the wintertime, the results showed 347	
that at a low, but relevant, dose of 15 µg/d, vitamin D3 was more efficacious than vitamin D2 348	
at raising total 25(OH)D.   This study is larger and more comprehensive than previous trials.    349	
We observed that although both vitamin D2 and D3 appeared to be effective in ensuring a 350	
sufficient vitamin D status for the white European participants (>50nmol/l) – e.g. 100% of 351	
European women who were in the vitamin D3 groups achieved serum 25(OH)D 352	
status >50nmol/l at the end of the 12 weeks, only ~90% of European women in the vitamin 353	
D2 groups achieved this level.   By comparison, for the South Asian women, ~ 70% of 354	
women who were in the vitamin D3 groups achieved serum 25(OH)d status >50 nmol/l at the 355	
end of the study compared to ~50% of South Asian women who were in the vitamin D2 356	
groups.  The South Asian women commenced the study within deficiency status whereas the 357	
white European women commenced the study largely sufficient, thus when 25OHD status is 358	
in the deficient range, such as in South Asians in this study, it would be more efficacious to 359	
raise levels by using vitamin D3 than vitamin D2.  Even this relatively low dose of 360	
fortification is effective and that use of large doses, as has been practice, to raise 25OHD, is 361	
not supported by these data.  362	
It was also demonstrated that food fortification is not only an effective and highly acceptable 363	
method of conveying vitamin D to the population, but that acidic beverages such as juice (that 364	
also contain virtually no fat) are equally effective as a fortification vehicle when compared to 365	
more pH-stable, higher fat baked goods.    366	
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The tests for interaction between the time visit, intervention group and ethnicity showed some 367	
interesting findings:  The time visit by intervention group interaction was significant across 368	
the board for the primary and secondary objectives.  This was the main focus of the study – 369	
whether vitamin D2 was different from vitamin D3 with respect to changes in total 25(OH)D 370	
status and their concomitant differences from the placebo group .  For total 25(OH)D status, 371	
where the interaction test involved ethnicity, the results were not significant, which was 372	
predictable given that our results showed no difference in the absolute rise in 25(OH)D status 373	
in response to fortification between white European and South Asian women.    However, the 374	
statistical results/trends for the ethnicity interactions with respect to 25(OH)D2 and 25(OH)D3 375	
status are intriguing and certainly warrant further investigation. 376	
Our main findings, showing greater efficacy of vitamin D3, is supported by a meta-analysis 377	
completed in 2012, which collated all studies to date that had directly compared the effects of 378	
vitamin D2 and D3 on total 25(OH)D (14). The meta-analysis indicated that vitamin D3 was 379	
more efficacious than vitamin D2 in raising total 25(OH)D. However the finding was mainly 380	
driven by studies using large single or intermittent bolus doses of vitamin D. Studies giving 381	
lower doses were largely unrepresentative, and the doses used (40-100 µg/d) were still higher 382	
than (a) global public health recommendations for daily consumption, and (b) intakes 383	
attainable without the use of supplements. Since the meta-analysis, there have been further 384	
randomized-controlled trials comparing vitamin D2 and D3 at lower daily doses (25-50 µg/d), 385	
although largely under-powered, that are consistent with our findings (18-20). Therefore this 386	
study strengthens the current evidence base, with provision of irrefutable data from a large 387	
cohort size following a robust study design.  	388	
An interesting result of our study is the response of the 25(OH)D metabolites; specifically the 389	
response of 25(OH)D3 to the vitamin D2 intervention, and 25(OH)D2 to the vitamin D3 390	
intervention. The decrease in 25(OH)D3 that was shown in the aggregated vitamin D2 group 391	
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(D2B and D2J combined; Figure 2) is consistent with previous findings from trials using daily 392	
doses of 25-100 µg/d (7, 19-21). Our study also showed a decrease in 25(OH)D2 in the 393	
vitamin D3 juice group, which has only previously been reported to have been found by 394	
Binkley and colleagues, although their data were not presented as too few participants had 395	
measureable 25(OH)D2 at baseline (7). Whether this finding has not been shown in previous 396	
studies due to low concentrations of 25(OH)D2 at baseline (typically <5 nmol/L) remains 397	
unclear, although Glendenning and colleagues found no change in 25(OH)D2 in their vitamin 398	
D3 group despite having higher baseline 25(OH)D2 (13.3 nmol/L)(12).  399	
A recent study by Oliveri and colleagues (22) took a pharmacokinetic approach to understand 400	
the mechanism behind the apparent difference in efficacy between vitamin D2 and D3. The 401	
group administered a loading dose (2,500 µg) at day 0, followed by two weeks of daily 402	
supplementation (120 µg/d, from day 7 to day 21) with either vitamin D2 or D3, and then a 56-403	
day clearance period. Their data shows that at both the post-loading dose phase (day 7) and 404	
post-daily dosage phase (day 21) there is no significant difference between groups, although 405	
the D3 group had higher concentrations of 25(OH)D; yet at end of the clearance phase, the D3 406	
group had significantly higher 25(OH)D than the D2 group. Oliveri and colleagues calculated 407	
that the elimination half-life of 25(OH)D for the D2 group was substantially shorter at 33 days 408	
when compared to 82 days for the D3 group (22).  409	
It is becoming clearer from both the literature and the results of this study, that there is a 410	
pronounced difference in the efficacy of vitamin D2 and D3 in raising total 25(OH)D. The 411	
mechanisms driving this differentiating factor appear to be focussed around the effect of 412	
vitamin D2 on 25(OH)D3, which indicates a possible mechanism encompassing competitive 413	
binding and differences in binding affinity between vitamin D2 and D3 with the vitamin D 414	
binding protein and hydroxylation enzymes. However, the shorter half-life of 25(OH)D2 415	
compared with 25(OH)D3 (22-23) also suggests that the elimination or degradation of 416	
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25(OH)D is another mechanism explaining the differences in the efficacy. To further expand 417	
this field and develop the mechanism, the in vivo behaviour of the CYP2R1 and CYP27B1 418	
enzymes must be understood.   419	
One of the strengths of the current study is the relevance of the dose chosen - matching the 420	
RDA set by the IOM of 15 µg/d for those aged 0-65 y to maintain 25(OH)D 421	
concentrations >50 nmol/L (1) and the use of vitamin D-fortified foods instead of 422	
supplements. As there is a lack of natural dietary sources of vitamin D (typical vitamin D 423	
intakes are 2.8 µg/d within the UK (24)), and the use of supplements by individuals could be 424	
erratic and unreliable, food fortification may be an important option for improving vitamin D 425	
intakes across a population. In the UK, where the dietary recommended value (DRV) for 426	
vitamin D has recently increased from 0 to 10 µg/d (25-26), considerable media attention and 427	
discussion has been focused on how this DRV will be achieved (27-28).  Therefore the use of 428	
the juice and biscuit were critical to demonstrate that if a food or beverage forms a habitual 429	
element of an individual’s diet, this could prove an effective and consistent method of 430	
providing vitamin D. In order to calculate the most effective level of fortification for 431	
improving vitamin D status, further research and modelling of the impact of fortification 432	
strategies is necessary, particularly looking at a combination of fortified foods and/or forms of 433	
vitamin D, as opposed to single staple food items which have previously been considered in 434	
modelling approaches (29-30). The primary strength of the D2-D3 Study is the fact that it is a 435	
larger cohort than previous studies comparing vitamin D2 to vitamin D3, with very good 436	
compliance. The study was conducted during the winter months, thus eliminating the 437	
confounding influence of UV exposure. The measurement of 25(OH)D2 and 25(OH)D3 also 438	
provides additional information that is key to understanding the potential mechanism behind 439	
the observed difference in response to vitamin D2 and D3. When compared to other studies in 440	
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the field, additional strengths of the study lay in the use of extended stratification of the 441	
intervention groups to ensure an equal spread of age, BMI and ethnicity.  442	
Limitations of the study centre on the lack of opportunity to generate dose response data. The 443	
provision of 15 µg/d of vitamin D2 or D3 as part of the study was appropriate given the current 444	
IOM RDA for vitamin D but, ideally, additional streams of intervention groups would have 445	
been implemented so that the same food fortification vehicles could be used but with differing 446	
doses of vitamin D2 and D3 fortification. Dose response data would have provided valuable 447	
insight into the physiological response to vitamin D and thus assisted in elucidating the 448	
mechanism behind the observed differences seen in the current data.  449	
Thus to extend the field of knowledge, future research should investigate the dose-response of 450	
vitamin D2 versus D3 at levels attainable by the general population, i.e. 5-20 µg/d. Additional 451	
analysis of vitamin D metabolites such as the vitamin D-binding protein and key 452	
hydroxylation enzymes would provide a more detailed context in which to evaluate the 453	
metabolism of vitamin D2 and D3.  454	
In conclusion, the D2-D3 Study is the most robust randomized controlled trial to date, that 455	
specifically compares the efficacy of a relatively low-dose vitamin D2 and vitamin D3 (15 456	
ug/d; 600 IU/d) on total serum 25(OH)D status during the wintertime in both Caucasians and 457	
South Asians. This study shows that vitamin D3 is superior in raising total serum 25(OH)D 458	
status when compared to vitamin D2, and may be most helpful in persons where baseline 459	
25(OH)D levels are below 50 nmol/L. However, both forms of vitamin D in fortified foods 460	
are effective at raising total 25(OH)D and preventing vitamin D deficiency (as defined as a 461	
25(OH)D status of <25nmol/l) during the wintertime.  462	
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Table 1: Characteristics of participants at baseline, per intervention group  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Data presented as mean ± SD.   
Key: yrs – years; m – metre; kg – kilograms; BMI – Body mass index; kg/m2 – kilograms per metre square; cm – centimetre; BP – Blood Pressure; mmHg – millimetres of mercury. 
 
 
Baseline anthropometrics 
 Placebo (n 65) D2 Juice (n 67) D2 Biscuit (n 66) D3 Juice (n 70) D3 Biscuit (n 67) 
Age (yrs) 44.1 ± 11.48 44.3 ± 11.18 43.2 ± 13.23 43.0 ± 12.73 43.7 ± 12.84 
Height (m) 1.64 ± 0.07 1.64 ± 0.07 1.64 ± 0.06 1.65 ± 0.06 1.64 ± 0.07 
Weight (kg) 65.8 ± 10.12 64.4 ± 8.30 64.8 ± 11.79 64.4 ± 10.28 63.6 ± 10.90 
BMI (kg/m2) 24.4 ± 3.62 24.2 ± 3.42 24.1 ± 4.45 23.8 ± 3.65 23.8 ± 3.82 
Waist Circumference (cm) 82.9 ± 10.76 81.9 ± 9.93 81.9 ± 11.83 81.0 ± 11.68 82.1 ± 11.86 
Waist:Hip Ratio 0.81 ± 0.08 0.81 ± 0.07 0.81 ± 0.07 0.79 ± 0.08 0.81 ± 0.08 
Body fat (%) 30.1 ± 6.87 30.1 ± 5.54 30.5 ± 6.36 29.9 ± 6.75 29.3 ± 7.81 
Systolic BP (mmHg) 118.9 ± 15.09 116.8 ± 14.78 120.0 ± 15.46 118.1 ± 12.69 117.4 ± 15.49 
Diastolic BP (mmHg) 78.7 ± 9.69 77.5 ± 9.51 79.3 ± 9.48 77.9 ± 9.83 77.2 ± 10.27 
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Table 2: Serum total 25-hydroxyvitamin D (25(OH)D) concentrations at baseline, 6 weeks and 12 weeks per intervention group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2:	Serum total 25(OH)D concentrations represented as mean (95%CI), sourced from non log-transformed data subjected to a general linear mixed model analysis.  
n indicates the numbers of participants randomised to each intervention group, who were then analysed as part of an Intention-to-Treat analysis plan regardless of participation.  
* indicates p<0.0001 for comparison between visit and baseline, within respective group (effect of time) for ‘All’ participants.  a – significant difference between D2J and D3J for 
‘All’ participants, p≤0.003; b – significant difference between D2B and D3B for ‘All’ participants, p≤0.002; Results for the significance levels of the tests of interaction were as 
follows:  The a) time visit x group interaction term was significant for the primary objective outcome measurements of total 25(OH)D (p<0.0004).   For total 25(OH)D status, there 
was a non-significant trend for  b) time visit x ethnicity (p<0.066) but no significant differences for  c) intervention group x ethnicity or d) time visit x intervention group x ethnicity.  
Model independent variables were: baseline 25OHD status, age, BMI, ethnicity,  time visit, intervention group and the following interactions – a) time visit by intervention group 
interaction; b) time visit by ethnicity interaction; c) ethnicity by intervention group interaction and d) time visit by ethnicity by intervention group interaction. 
 Intervention Groups 
Total 25(OH)D (nmol/l) Placebo (n 65) D2 Juice (n 67) D2 Biscuit (n 66) D3 Juice (n 70) D3 Biscuit (n 67) 
Week 0 (baseline) 
All 
South Asian 
White European 
44.8 (37.5, 52.1) 
30.8 (18.3, 43.3) 
58.8 (51.4, 66.2) 
44.9 (37.8, 52.0) 
29.5 (17.3, 41.6) 
60.3 (52.9, 67.7) 
46.1 (38.9, 53.4) 
30.5 (18.0, 42.9) 
61.8 (54.4, 69.1) 
42.3 (35.4, 49.2) 
27.3 (15.5, 39.2) 
57.3 (50.1, 64.5) 
41.9 (34.9, 48.9) 
20.5 (8.7, 32.3) 
63.4 (55.9, 70.8) 
Week 6 (mid-intervention) 
All 
South Asian 
White European 
36.2 (30.4, 41.9)* 
23.2 (13.3, 33.1) 
49.2 (43.3, 55.0) 
58.7 (53.1, 64.4)*a 
45.7 (35.9, 55.5) 
71.7 (66.0, 77.4) 
58.6 (52.9, 64.4)*b 
44.9 (34.9, 54.8) 
72.4 (66.6, 78.2) 
69.0 (63.3, 74.8)*a 
54.3 (44.2, 64.4) 
83.7 (78.1, 89.3) 
67.7 (61.9, 73.5)*b 
47.6 (37.6, 57.6) 
87.8 (82.0, 93.6) 
Week 12 (end of trial) 
All 
South Asian 
White European 
33.5 (27.8, 39.3)* 
23.3 (13.3, 33.2) 
43.8 (38.0, 49.6) 
59.7 (53.9, 65.4)*a 
47.2 (37.2, 57.2) 
72.2 (66.5, 77.9) 
61.9 (56.0, 67.7)*b 
48.6 (38.5, 58.6) 
75.2 (69.3, 81.0) 
74.0 (68.1, 79.9)*a 
60.1 (49.7, 70.5) 
87.9 (82.3, 93.5) 
73.0 (67.1, 78.9)*b 
53.2 (42.9, 63.4) 
92.8 (87.0, 98.6) 
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Table 3: Serum 25(OH)D2, 25(OH)D3, calcium and parathyroid hormone (PTH) concentrations at baseline, 6 weeks and 12 weeks per 
intervention group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3: Vitamin D metabolites, parathyroid hormone and corrected calcium concentrations represented as geometric mean (95%CI), sourced from logarithmically-transformed data 
subjected to a general linear mixed model analysis. n indicates the numbers of participants randomised to each intervention group, who were then analysed as part of an Intention-to-
Treat model at the end of the trial, regardless of participation. * indicates p<0.001 for comparison between visit and baseline, within respective group (effect of time).  a – significant 
difference between D2J and D3J, p<0.002; b – significant difference between D2B and D3B, p<0.003.  Results for the significance levels of the tests of interaction were as follows:  
The a) time visit x group interaction term was significant for all the secondary objective outcome measurements including total 25(OH)D, PTH, 25(OH)D2 and 25(OH)D3 (p<0.0004 
 Intervention Groups 
 Placebo (n 65) D2 Juice (n 67) D2 Biscuit (n 66) D3 Juice (n 70) D3 Biscuit (n 67) 
Week 0 (baseline) 
25(OH)D2 (nmol/l) 
25(OH)D3 (nmol/l) 
1.38 (1.05, 1.82) 
32.1 (27.5, 37.6) 
0.97 (0.74, 1.27) 
33.7 (28.9, 39.3) 
1.23 (0.94, 1.62) 
33.7 (28.8, 39.4) 
1.14 (0.88, 1.48) 
30.9 (26.6, 35.9) 
1.14 (0.87, 1.49) 
29.4 (25.3, 34.2) 
Adj. Calcium (mmol/l) 2.23 (2.21, 2.25) 2.24 (2.23, 2.26) 2.25 (2.23, 2.27) 2.25 (2.23, 2.27) 2.23 (2.22, 2.25) 
PTH (pmol/l) 4.99 (4.48, 5.57) 5.17 (4.64, 5.75) 4.89 (4.38, 5.45) 4.85 (4.37, 5.38) 5.01 (4.51, 5.57) 
Week 6 (mid-intervention) 
25(OH)D2 (nmol/l) 
25(OH)D3 (nmol/l) 
1.37 (1.10, 1.71) 
25.4 (22.3, 28.9)* 
28.60 (22.99, 35.57)*a 
20.8 (18.3, 23.6)*a 
26.59 (21.30, 33.20)*b 
22.7 (19.9, 25.8)*b 
0.82 (0.66, 1.03)*a 
61.4 (54.0, 69.8)*a 
1.07 (0.85, 1.35)b 
61.5 (54.0, 69.9)*b 
Adj. Calcium (mmol/l) 2.20 (2.18, 2.22)* 2.19 (2.17, 2.21)* 2.19 (2.18, 2.21)* 2.20 (2.18, 2.22)* 2.19 (2.17, 2.21)* 
PTH (pmol/l) 4.96 (4.45, 5.52) 4.93 (4.43, 5.48) 4.94 (4.43, 5.51) 4.58 (4.10, 5.12) 4.77 (4.27, 5.33) 
Week 12 (end of trial) 
25(OH)D2 (nmol/l) 
25(OH)D3 (nmol/l) 
1.59 (1.25, 2.02) 
24.3 (21.2, 27.7)* 
29.54 (23.21, 37.58)*a 
17.0 (14.9, 19.5)*a 
31.27 (24.56, 39.82)*b 
21.4 (18.7, 24.5)*b 
0.89 (0.69, 1.14)*a 
65.4 (57.1, 74.9)* a 
1.17 (0.91, 1.51)b 
64.9 (56.6, 74.3)*b 
Adj. Calcium (mmol/l) 2.28 (2.26, 2.31)* 2.30 (2.28, 2.32)* 2.29 (2.27, 2.31)* 2.29 (2.27, 2.32)* 2.29 (2.27, 2.32)* 
PTH (pmol/l) 5.27 (4.69, 5.91) 4.65 (4.14, 5.22)* 4.73 (4.21, 5.31) 3.98 (3.54, 4.49)* 4.13 (3.66, 4.66)* 
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to p<0.0001 respectively).   For PTH, b) time visit x ethnicity interaction was not significant and neither was c) intervention group x ethnicity.   For d) time visit x intervention group 
x ethnicity interaction, this was significant (p<0.04).   For 25(OH)D2, b) no significant interactions were found for time visit x ethnicity, but for c) a significant interaction was shown 
for intervention group x ethnicity (p<0.001),  and for d) time visit x intervention group x ethnicity (p<0.01).  Similar findings were found for 25(OH)D3:  b) time visit x ethnicity 
interaction was significant (p<0.0067) and  c) intervention group x ethnicity interaction was significant (p<0.0001) and d)  a non-significant trend for time visit x intervention group 
x ethnicity interaction (p<0.1).    
Key: Adj. Calcium – Serum calcium concentration adjusted for concomitant albumin level, using the formula [(40 - albumin) x 0.02] + Calcium. PTH – Parathyroid Hormone. 
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Figure legends: 
 
Figure 1: Consolidated Standards of Reporting Trials (CONSORT) flow diagram indicating the 
number of participants screened, recruited, randomized and analysed as part of the D2D3 Study. 
 
Figure 2: Vitamin D metabolite responses per aggregated intervention group. Geometric mean 
(95%CI) serum concentrations per time point are shown, sourced from log-transformed data 
subjected to a general linear mixed model analysis (Intention-to-treat). (A) 25(OH)D2. (B) 
25(OH)D3. Placebo group n 65, D2 group n 133, D3 group n 137. a – significant difference between 
placebo and D2 group over the intervention period, p<0.0005; b - significant difference between 
placebo and D3 group over the intervention period, p<0.0005; c - significant difference between D2 
and D3 group over the intervention period, p<0.003.  
Key:  D3 aggregated intervention group;  D2 aggregated intervention group;  Placebo 
group 
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